Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics (NASDAQ: ALGS), a clinical stage biopharmaceutical company specializing in liver and viral diseases, has announced an inducement grant for a newly hired employee. The grant, approved by the Company's Compensation Committee, consists of non-qualified stock options to purchase 26,000 shares of company stock.
The options were granted on May 13, 2025, with an exercise price equal to the closing price on the grant date. The shares will vest over 4 years, with 25% vesting after the first year and the remainder vesting monthly thereafter, contingent on continued employment. This grant was made under Aligos' 2024 Inducement Plan, specifically designed for equity awards to new hires, in compliance with Nasdaq Listing Rule 5635(c)(4).
Aligos Therapeutics (NASDAQ: ALGS), un'azienda biofarmaceutica in fase clinica specializzata in malattie del fegato e virali, ha annunciato una concessione di incentivi per un nuovo dipendente. La concessione, approvata dal Comitato per la Remunerazione della Società, consiste in opzioni azionarie non qualificate per l'acquisto di 26.000 azioni della società.
Le opzioni sono state concesse il 13 maggio 2025, con un prezzo di esercizio pari al prezzo di chiusura alla data di concessione. Le azioni matureranno in un periodo di 4 anni, con il 25% che matura dopo il primo anno e il resto che matura mensilmente successivamente, a condizione che l'impiego continui. Questa concessione è stata effettuata nell'ambito del Piano di Incentivi 2024 di Aligos, progettato specificamente per premi azionari ai nuovi assunti, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
Aligos Therapeutics (NASDAQ: ALGS), una compañía biofarmacéutica en etapa clínica especializada en enfermedades hepáticas y virales, ha anunciado una concesión de incentivos para un empleado recién contratado. La concesión, aprobada por el Comité de Compensación de la Compañía, consiste en opciones sobre acciones no calificadas para comprar 26,000 acciones de la empresa.
Las opciones fueron otorgadas el 13 de mayo de 2025, con un precio de ejercicio igual al precio de cierre en la fecha de concesión. Las acciones se consolidarán durante 4 años, con un 25% consolidándose después del primer año y el resto consolidándose mensualmente a partir de entonces, condicionado a la continuidad del empleo. Esta concesión se realizó bajo el Plan de Incentivos 2024 de Aligos, diseñado específicamente para premios en acciones a nuevos empleados, en cumplimiento con la Regla de Cotización Nasdaq 5635(c)(4).
Aligos Therapeutics(NASDAQ: ALGS)는 간 및 바이러스 질환을 전문으로 하는 임상 단계 바이오제약 회사로, 신입 사원을 위한 인센티브 부여를 발표했습니다. 회사 보상 위원회에서 승인한 이 부여는 회사 주식 26,000주를 매수할 수 있는 비자격 스톡옵션으로 구성되어 있습니다.
옵션은 2025년 5월 13일에 부여되었으며, 행사 가격은 부여일 종가와 동일합니다. 주식은 4년에 걸쳐 베스팅되며, 첫 해 후 25%가 베스팅되고 이후 매월 나머지가 베스팅되며, 계속 근무 조건이 붙습니다. 이 부여는 Nasdaq 상장 규칙 5635(c)(4)를 준수하여 신입 사원에게 주식 보상을 제공하기 위해 특별히 설계된 Aligos의 2024년 인센티브 플랜에 따라 이루어졌습니다.
Aligos Therapeutics (NASDAQ : ALGS), une société biopharmaceutique en phase clinique spécialisée dans les maladies hépatiques et virales, a annoncé une attribution d'incitation pour un nouvel employé. L'attribution, approuvée par le comité de rémunération de la société, consiste en des options d'achat d'actions non qualifiées permettant d'acquérir 26 000 actions de la société.
Les options ont été accordées le 13 mai 2025, avec un prix d'exercice égal au cours de clôture à la date d'attribution. Les actions seront acquises sur une période de 4 ans, avec 25 % acquis après la première année et le reste acquis mensuellement par la suite, sous réserve de la poursuite de l'emploi. Cette attribution a été réalisée dans le cadre du Plan d'Incitation 2024 d'Aligos, spécialement conçu pour les attributions d'actions aux nouvelles recrues, conformément à la règle de cotation Nasdaq 5635(c)(4).
Aligos Therapeutics (NASDAQ: ALGS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Leber- und Viruskrankheiten spezialisiert hat, hat eine Anreizzuteilung für einen neu eingestellten Mitarbeiter angekündigt. Die vom Vergütungsausschuss des Unternehmens genehmigte Zuteilung besteht aus nicht qualifizierten Aktienoptionen zum Kauf von 26.000 Aktien des Unternehmens.
Die Optionen wurden am 13. Mai 2025 gewährt, mit einem Ausübungspreis, der dem Schlusskurs am Zuteilungsdatum entspricht. Die Aktien werden über 4 Jahre erworben, wobei 25 % nach dem ersten Jahr und der Rest monatlich danach vesten, vorausgesetzt, die Beschäftigung wird fortgesetzt. Diese Zuteilung erfolgte im Rahmen des Aligos 2024 Inducement Plans, der speziell für Aktienprämien an Neueinstellungen entwickelt wurde und den Nasdaq-Listing-Regel 5635(c)(4) entspricht.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 26,000 shares of the Company’s stock (the “Inducement Grant”) to a newly hired employee on May 13, 2025 (the “Grant Date”), in connection with the commencement of employment.
The Inducement Grant was granted pursuant to Aligos’ 2024 Inducement Plan (the “Plan”) as an inducement material to this individual entering employment in accordance with Nasdaq Listing Rule 5635(c)(4). The Plan is used exclusively for the grant of equity awards to individuals who were not previously employed by Aligos.
The Inducement Grant has an exercise price per share equal to the closing price of Aligos’ common stock on the Grant Date. The shares subject to the Inducement Grant will vest over a four-year period, with
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus infection, metabolic dysfunction-associated steatohepatitis (MASH), and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Aligos Therapeutics
Contact
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
+1 (650) 910-0427
jtarazi@aligos.com
FAQ
What is the vesting schedule for ALGS's May 2025 inducement grant?
How many shares were included in Aligos Therapeutics' May 2025 inducement grant?
What is the purpose of ALGS's 2024 Inducement Plan?
What is the exercise price for the ALGS inducement grant issued in May 2025?
